T cell costimulatory blockade as a novel immune intervention in autoimmune diseases

Clinics in Dermatology

Volumn 19, Issue 5, 2001, Pages 586-591

  Najafian, Nader ^a   Khoury, Samia J ^a   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 39;

ANIMAL MODEL; AUTOIMMUNE DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

AUTOIMMUNE DISEASES; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNITY, CELLULAR; MAJOR HISTOCOMPATIBILITY COMPLEX; SENSITIVITY AND SPECIFICITY; SKIN DISEASES; SKIN PHYSIOLOGY; T-LYMPHOCYTES;

EID: 0034805525     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(00)00172-3     Document Type: Review

References (54)

1. A cell culture model for T lymphocyte clonal anergy
2. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
3. The role of T-cell costimulatory activation pathways in transplant rejection
4. A theory of self-nonself discrimination
5. The role of the CD28 receptor during T cell responses to antigen
6. The B7 and CD28 receptor families
7. CTLA-4 is a second receptor for the B cell activation antigen B7
8. CTLA-4ligation blocks CD28-dependent T cell activation
9. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
10. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
11. CTLA-4 can function as a negative regulator of T cell activation
12. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
13. CD28 costimulation prevents cell death during primary T cell activation
14. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
15. Role of Fas-mediated cell death in the regulation of immune responses
16. Homeostasis and self-tolerance in the immune system; Turning lymphocytes off
17. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
18. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes
19. CTLA-4; A negative regulator of autoimmune disease
20. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice
21. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness
22. Keratinocyte expression of B7-1 in transgenic mice amplifies the primary immune response to cutaneous antigens
23. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions
24. Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis
25. Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases
26. T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1; A ligand for CD28
27. Organ injury associated with extrathymic induction of immune tolerance in doubly transgenic mice
28. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction
29. Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic beta cells
30. Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells
31. The role of CD40 in the regulation of humoral and cell-mediated immunity
32. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection
33. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal
34. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H
35. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides
36. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion
37. Treatment of murine lupus with CTLA4Ig
38. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis
39. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
40. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis
41. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis
42. CD28-B7costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
43. Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand
44. Blockade of CD40-CD40 ligand pathway induces tolerance in murine contact hypersensitivity
45. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
46. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival
47. B7-1 and B7-2 costimulatory molecules differentially activate the TH1/TH2 developmental pathways; Application to autoimmune disease therapy
48. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice
49. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis
50. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis
51. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes
52. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways
53. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
54. Finally, CTLA4Ig graduates to the clinic